In the News

Sep 14, 2022

BioSpace

Regeneron, Immutep Talk LAG-3 as ESMO Highlights New I-O Approaches

Aug 02, 2022

OncLive

Eftilagimod Alpha/Pembrolizumab Combo Elicits Encouraging Survival Benefits in Anti–PD-1/PD-L1 Refractory NSCLC

Jul 06, 2022

MedPage Today

Efti, Pembrolizumab Doublet Continues to Impress in Metastatic NSCLC

Jul 27, 2022

OncLive

LAG-3 Fills a Complex Role in the Immune System

Jun 02, 2022

The Australian

How Immutep and other immunotherapy biotechs have changed cancer treatment

Media

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 19 May 2023 – Executive Director and CEO Marc Voigt discusses the significance of recent announcements on the back of a recent surge in trading volume.

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 01 Mar 2023 – Executive Director and CEO Marc Voigt discusses data from SITC, the strategy to take Efti to market and milestones for 2023.

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 28 Nov 2022 – CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company's portfolio of therapies, encouraging data from the 2022 SITC conference and the outlook for 2023.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 12 Oct 2022 – CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company's new Phase 2 trial in soft tissue sarcoma and the outlook ahead.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 06 Apr 2022 – From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep's Executive Director and CEO, Marc Voigt.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 30 Mar 2022 – Executive Director and CEO Marc Voigt discusses the company's LAG-3-related therapies, outlining future plans and expected data readouts for Immutep's lead drug, eftilagimod alpha.